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The chondrocyte is responsible for the precise production of
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lular matrix, which is the main functional component of cartilaginous tissues, is crucial. The expression of extracellular
matrix molecules by chondrocytes must, therefore, be tightly
and coordinately controlled at the level of both synthesis and
degradation to ensure that the matrix is properly constructed
and maintained. Part of this control occurs at the level of the
regulation of chondrocyte-specific gene expression. The best
studied gene in this regard is the COL2A1 gene, which gives
rise to the main fibrillar collagen in the cartilage matrix. The
expression of the COL2A1 gene is controlled through transcription factors that interact with both the promoter and the chondrocyte-specific enhancer located within the first intron (1– 4).
Recent work has shown that both positive and negative factors
interact with the COL2A1 gene to regulate its expression (2– 8).
Positive regulation of the COL2A1 gene during chondrocyte
differentiation is afforded by the interaction of members of the
Sry-type HMG box (SOX)1 family of transcription factors with
a specific region of the intronic enhancer (5– 8). Three SOX
factors, L-SOX5, SOX6, and SOX9, have been shown to cooperatively activate the expression of the COL2A1 gene, and SOX9
has been shown to be essential for normal skeletogenesis (6, 9,
10).
Despite the wealth of information concerning the control of
expression of the COL2A1 gene, relatively little is known about
the transcriptional regulation of other chondrocyte-specific collagen genes, including those encoding collagens that interact
with type II collagen, such as types IX and XI (11, 12). Collagen
IX is a member of a subfamily of collagens termed fibril-associated collagens with interrupted-triple helices (FACITs) that
also include collagens XII, XIV, XVI, and XIX (13, 14). Collagen
IX is a heterotrimeric molecule composed of three polypeptide
chains (␣1(IX), ␣2(IX), and ␣3(IX)) each containing three collagenous domains (COL1–3) interrupted by four non-triplehelical domains (NC1–NC4) (15, 16). The NC1, NC2, and NC3
domains are of similar size in all three chains, whereas the
NC4 domain of the ␣1(IX) chain is much larger than in the
␣2(IX) and ␣3(IX) chains (17, 18). Indeed, the NC4 domain of
the ␣1(IX) chain is encoded by exons 1– 8 in the COL9A1 gene,
which are expressed through the use of the cartilage-specific
promoter region studied in the present work (19, 20). A second
promoter, located between exons 6 and 7, is utilized in other
tissues to express a short form of the ␣1(IX) chain that lacks
the large NC4 domain (19, 20). Interestingly, mice that lack
type IX collagen develop normally but exhibit a late-onset form
of joint degeneration similar to osteoarthritis, suggesting a
stabilizing role for type IX collagen in cartilage (21, 22).
The purpose of this study was to examine the regulatory
elements located within the proximal promoter region of the
1
The abbreviations used are: SOX, Sry-type HMG box; EMSA, electrophoretic mobility-shift assay; RCS, rat chondrosarcoma; HTB, human chondrosarcoma.

117

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on February 17, 2017

The COL9A1 gene contains two promoter regions, one
driving expression of a long ␣1(IX) chain in cartilage
(upstream) and one driving expression of a shorter
chain in the cornea and vitreous (downstream). To determine how the chondrocyte-specific expression of the
COL9A1 gene is regulated, we have begun to characterize the upstream chondrocyte-specific promoter region
of the human COL9A1 gene. Transient-transfection analyses performed in rat chondrosarcoma (RCS) cells, human chondrosarcoma (HTB) cells, and NIH/3T3 cells
showed that the COL9A1 promoter was active in RCS
cells but not HTB or NIH/3T3 cells. Inclusion of the first
intron had no effect on promoter activity. In transienttransfection analyses with promoter deletion constructs, it was found that full promoter activity in RCS
cells depended on the region from ⴚ560 bp to ⴙ130 bp
relative to the transcriptional start site (ⴙ1). Sequence
analysis of the region from ⴚ890 bp to the transcriptional start predicted five putative SOX/Sry-binding
sites. Mutation analysis revealed that two of three putative SOX/Sry binding sites within the ⴚ560 to ⴙ130 bp
region are responsible for most of the COL9A1 promoter
activity in RCS cells. Co-transfection experiments with
a SOX9 expression plasmid revealed that a construct
containing the five putative SOX/Sry-binding sites was
transactivated 20- to 30-fold in both HTB and NIH/3T3
cells. Further co-transfection experiments showed that
two of the SOX/Sry-binding sites located within the ⴚ560
to ⴙ130 bp region were required for full transactivation.
However, mutation and deletion analyses indicated that
a region from ⴚ560 to ⴚ357 bp, which does not contain
any other conspicuous SOX9 sites, is also important for
full promoter activity. DNA-protein binding assays and
super-shift analysis revealed that SOX9 can form a specific complex with one of the SOX/Sry-binding sites with
in the ⴚ560 to ⴙ130 region.
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human COL9A1 gene in chondrocytic cells. We found that a
976-bp promoter fragment from the human COL9A1 gene was
able to drive expression of reporter genes in RCS cells. We also
found that this promoter region can be transactivated to high
levels by SOX9 in nonchondrocytic NIH/3T3 and human chondrosarcoma cells (HTB). We show that the SOX9 transactivation depends on two of five putative SOX/Sry-binding sites by
mutational analysis and that a third region that does not
contain any obvious SOX/Sry-binding sites is also important for
full promoter activity. Finally, we provide evidence that SOX9
can interact with one of the functionally active aforementioned
SOX/Sry-binding sites.
MATERIALS AND METHODS

Cell Culture—Rat chondrosarcoma cells (RCS) were a kind gift from
Dr. Benoit de Crombrugghe (23). HTB human chondrosarcoma cells
(SW1353) and NIH/3T3 fibroblasts were obtained from American Type
Culture Collection. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, high glucose), 10% fetal bovine serum supplemented with L-glutamine (2 mM), penicillin (100 units/ml), streptomycin
(100 g/ml), fungizone (2.5 g/ml), and ascorbic acid (50 g/ml). Cells
were split at 70 – 80% confluence, and the medium was replaced every
3– 4 days.
COL9A1-Luciferase Constructs—The human COL9A1 proximal promoter region and first intron were obtained by PCR using a P1 phage
clone (P1-A) that contains the 5⬘ region of the human COL9A1 gene (a
kind gift from Dr. Lena Ala-Kokko; ref. 20) and the following primers.
For the promoter region: primer DS37, 5⬘-GATCGAATTCAGTAGGGGGCTTGATGTTA-3⬘ (forward) and primer DS38, 5⬘-GATCCTCGAGTTCCCAGTTGATTTTCTTTG-3⬘ (reverse), and for the first intron:
primer DS39, 5⬘-GATCGTCGACAAGACAATAACCCTGGAAAGA-3⬘
(forward) and primer DS40, 5⬘-GATCAAGCTTTGAAACAGGAGTCCCCGCAGA-3⬘ (reverse). The primers for the promoter region contained an EcoRI and a XhoI site, respectively, and the primers for the
first intron contained a SalI and a HindIII site, respectively, to facilitate cloning. The PCR-generated promoter fragment (976 bp) contained
the region from ⫺846 to ⫹130 relative to the transcriptional start site,
and the first intron fragment (807 bp) contained from position ⫹1037 to
⫹1843 in the human COL9A1 gene sequence (excluding the splice-site
sequences) (20). The promoter fragment was cloned into the NheI-XhoI
sites of the pGL3basic luciferase-reporter vector (Promega, Madison,
WI) to generate the full-length 846Luc promoter construct. To generate

the 846LucInt construct, the intron fragment was cloned into the HindIII-SalI sites of 846Luc. The various COL9A1 promoter-deletion constructs were generated by PCR using different forward primers (see
below) in combination with the same reverse primer (DS38, see above).
For construct 588Luc, 5⬘-AATGATTGTTGGGTGTTAGAC-3⬘; for construct 560Luc, 5⬘-GATCGCTAGCCTTTGATACCTCATTT-3⬘; for construct 357Luc, 5⬘-GTGGGCACATTTTTACTGGA-3⬘; for construct
167Luc, 5⬘-TTCCCCTGTAAATCCCTCCTTC-3⬘, and for construct
107Luc, 5⬘-GATCGCTAGCCTGGGCTCAGAGCGCT-3⬘. In the case of
the primers for constructs 560Luc and 107Luc, NheI sites were placed
into the 5⬘ end to facilitate cloning. The deletion-PCR products for
588Luc, 357Luc, and 167Luc were cloned into the SmaI-XhoI sites of
pGL3basic, and the PCR products for 560Luc and 107Luc were cloned
into the NheI-XhoI sites of pGL3basic. For the pGL3ProC construct, an
85-bp PCR product encompassing the region from ⫺559 to ⫺475 was
cloned into the pGL3promoter vector (Promega), which contains the
SV40 promoter linked to the luciferase reporter gene. The pGL3ProD
construct was made in a similar manner by inserting a 96-bp PCR
fragment encompassing the region from ⫺356 to ⫺261 into the
pGL3promoter vector. All PCR products were verified by sequencing on
an ABI automatic DNA sequencer (PerkinElmer Life Sciences).
Transient Transfection and Luciferase Assays—Seven to ten g of the
various COL9A1 reporter constructs, 2 g of the SOX expression vectors (a kind gift from Dr. Veronique Lefebvre, 6), and 2 g of the pCMV␤
reporter vector (Clontech), as a control for transfection efficiency, were
co-transfected into either RCS, HTB, or NIH/3T3 cells by the calcium
phosphate precipitation method using the Profection kit (Promega). The
cells were plated 24 h before transfection at a density of 5 ⫻ 105 cells per
10 cm2 dish. The DNA-CaPO4 precipitate was left on the cells for 16 –18
h, after which the cells were washed 3 times with phosphate-buffered
saline followed by the addition of fresh media. Forty-eight h after
transfection, the cells were harvested and luciferase assays were performed with a luciferase assay kit (Promega) and a Turner Designs TD
20/20 luminometer (Turner Designs, Sunnyvale, CA). ␤-Galactosidase
assays were performed spectrophotometrically with a ␤-galactosidase
enzyme assay system (Promega). Protein concentrations in the cell
lysates were determined using the Coomassie Blue protein assay
(Pierce). Luciferase activity was normalized to both ␤-galactosidase
activity and protein concentration. Transfection data represent at least
two independent experiments each performed in triplicate, except
where indicated.
Nuclear Extracts and Electrophoretic Mobility-shift Assays—Nuclear
extracts were prepared according to the method of Dignam et al. (24)
using the CellLytic NuCLEAR extraction kit (Sigma-Aldrich). Briefly,
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FIG. 1. Relative activity of the human COL9A1 promoter in RCS, HTB, and NIH/3T3 cells. A, schematic illustration of the human
COL9A1 promoter and promoter-intron luciferase-reporter constructs. The 846Luc construct contains an 846-bp COL9A1 gene fragment encompassing the promoter region and part of the first exon (not including the ATG translational start codon) and the 846LucInt construct contains an
807-bp gene fragment encompassing the first intron (not including the 5⬘- and 3⬘-splice site sequences). B, activity of the 846Luc construct in RCS,
HTB, and NIH/3T3 cells. The cells were co-transfected with 10 g of the 846Luc construct or the pGL3basic empty vector and 2 g of the pCMV␤
plasmid. C, effect of the first intron on promoter activity in RCS cells. The 846Luc or 846LucInt constructs, or the pGL3basic empty vector were
co-transfected with the pCMV␤ plasmid into RCS cells. Transfected cells were incubated for 48 h and then luciferase and ␤-galactosidase activities
were determined as described under “Materials and Methods.” Data are presented as average -fold difference of luciferase activity versus control
(pGL3basic) vector ⫾ S.D., or as average percent of control (pGL3basic) ⫾ S.D.
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cells were placed in hypotonic buffer (10 mM HEPES [pH 7.9], 1.5 mM
MgCl2, 10 mM KCl, and 0.5 mM dithiothreitol) and incubated on ice for
15 min. Igeapal CA-630 was added to a final concentration of 0.6%, and
the mixture was vortexed vigorously for 10 s. Nuclei were recovered by
centrifugation at 3,300 ⫻ g for 30 s at 4 °C and extracted in buffer
containing 20 mM HEPES pH 7.9, 0.42 M NaCl, 25% glycerol, 1.5 mM
MgC12, 0.2 mM EDTA, and 0.5 mM dithiothreitol for 30 min at 4 °C by
gentle shaking. The extract was then centrifuged for 15 min at 25,000 ⫻
g, and the supernatant was frozen at ⫺70 °C. All buffers contained a
protease inhibitor mixture (2 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 1.4 pM trans-epoxysuccinyl-L-leucylamido [4-guanidinobutane],
130 pM bestatin, 1 M leupeptin, and 0.3 pM aprotinin; Sigma-Aldrich).
Electrophoretic mobility-shift assays (EMSAs) were carried out as
previously described with minor modifications (25). Briefly, binding
reactions consisted of 12.5 mM Hepes, pH 7.9, 50 –100 mM NaCl, 5%
glycerol, 2 mg/ml bovine serum albumin, 2 g poly(dG-dC), 0.1 mM
EDTA, 0.1 mM dithiothreitol, 1 ng of 32P-end labeled double-stranded
oligonucleotide probe, and 10 –15 g of nuclear protein. Binding reactions were incubated for 30 min at 21 °C and then loaded onto 4%
acrylamide-0.25⫻ Tris borate-EDTA gels and electrophoresed at 200 V
for 2 h. For competition analyses, 50-fold excess of cold-competitor
probe was included in the binding reaction. For super-shift analyses, 3
l of a rabbit polyclonal anti-SOX9 antibody (a kind gift from Dr.
Veronique Lefebvre; Ref. 6) was included in the binding reaction.
RESULTS

Human COL9A1 Promoter Activity in Different Cells and the
Effect of the First Intron on COL9A1 Promoter Activity—A
luciferase reporter gene construct (846Luc) containing a 976-bp
COL9A1 gene fragment that includes 846 bp of the promoter
and 130 bp of the first exon (up to but not including the ATG
initiation codon) (Fig. 1A) was transfected into RCS, HTB chondrosarcoma, and NIH/3T3 cells to determine the relative promoter activity as compared with the pGL3basic vector (no

promoter). The 846Luc construct exhibited a high level of promoter activity in the chondrocytic RCS cells (⬃18-fold over the
vector alone, Fig. 1B), however, in HTB and NIH/3T3 cells, the
COL9A1 promoter activity was substantially lower (Fig. 1B).
To examine whether the first intron of the human COL9A1
gene contains transcriptional regulatory elements, an 807-bp
fragment containing the first intron (excluding the splice-site
sequences at the 5⬘ and 3⬘ ends) was inserted into the 846Luc
construct to obtain 846LucInt. The two constructs, 846Luc and
846LucInt, were then separately transfected into RCS cells. As
can be seen in Fig. 1C, inclusion of the COL9A1 first intron
fragment did not result in any significant difference in promoter activity.
Transactivation of the COL9A1 Promoter by SOX9 —SOX
transcription factors have been shown to be important for the
regulation of chondrocyte-specific gene expression. Sequence
analysis of the proximal promoter region of the human
COL9A1 gene with the MatInspector program (26) revealed
five putative SOX/Sry-binding sites (Fig. 2A), whereas analysis
of the first intron did not reveal any recognizable SOX/Srybinding sites. To determine whether SOX9 regulates the activity of the COL9A1 gene, either the 846Luc or the 846LucInt
construct were co-transfected with a SOX9 expression construct into HTB and NIH/3T3 cells. SOX9 overexpression in
these cells activated the 846Luc and 846LucInt constructs by
⬃25- to 30-fold (Fig. 2, B and C). However, there was no
difference in activation between the two constructs in response
to SOX9, indicating that the observed transcriptional activation depends on the proximal-promoter region and that the first
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FIG. 2. SOX9 transactivates the human COL9A1 proximal promoter region in NIH/3T3 and HTB cells. A, sequence of the human COL9A1proximal
promoter region. Shown in bold and underlined are the 5 putative SOX/Sry-binding sites designated A–E. Brackets denote
the regions that were used to construct
the pGL3proC and pGL3proD constructs
in Fig. 6. Shown below the sequence for
comparison is the HMG-SOX/Sry-binding
site consensus sequence (5). B, transactivation of the 846Luc and 846LucInt reporter constructs in HTB cells by cotransfection with a SOX9 expression
vector. Ten micrograms of either 846Luc
or 846LucInt were transfected into HTB
cells with 2 g of pBluescript or a SOX9
expression vector and 2 g of pCMV␤. C,
transactivation of 846Luc and 846LucInt
by co-transfection with a SOX9 expression vector in NIH/3T3 cells. NIH/3T3
cells were transfected as in B. Transfected cells were incubated for 48 h, and
luciferase and ␤-galactosidase activities
were determined as described in “Materials and Methods.” Data are presented as
average -fold difference of luciferase activity versus control (846Luc, no SOX9) ⫾
S.D.
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intron did not have any influence on the transcriptional activity of the gene under these conditions.
Deletion Analysis of the COL9A1 Proximal Promoter Region—To delineate which regions of the COL9A1 promoter
region are responsible for promoter activity and SOX9 transactivation, a series of COL9A1-promoter-luciferase 5⬘-deletion
constructs were employed (Fig. 3A). The deletion constructs
were generated such that the five putative SOX/Sry-binding
sites, designated A–E, were sequentially removed (Figs. 2A and
3A). To determine the effect of the deletions on promoter activity, the full-length construct (846Luc) and the five deletion
constructs (588Luc, 560Luc, 357Luc, 167Luc, and 107Luc)
were transfected into RCS cells (Fig. 3B). Deletion of up to 286
bp from the 5⬘ end, including the two distal putative SOX/Srybinding sites (588Luc and 560Luc, sites A and B in Fig. 3A) did
not result in any substantial changes in activity in RCS cells
(Fig. 3B). However, when the region containing the three distal
putative SOX/Sry sites was removed (357Luc, sites A–C in Fig.
3A), the promoter activity was reduced to 20% of control (Fig.
3B). Deletion of the region encompassing the four distal sites
(167Luc, sites A–D in Fig. 3A) resulted in slightly increased
expression as compared with the 357Luc construct (sites A–C
deleted) and an overall expression level of 31% of control (Fig.
3B). Finally, deletion of the region encompassing all five sites
(107Luc in Fig. 3A) resulted in a 5.5-fold decrease in promoter
activity (9% of control, Fig. 3B). We conclude that the region
encompassing the SOX/Sry-binding sites C–E is important for
full promoter activity in RCS cells.
To determine which of the putative SOX/Sry sites within the
proximal promoter region were responsible for the observed
transactivation by SOX9, the various deletion constructs were

FIG. 4. Transactivation of COL9A1-promoter-deletion constructs by SOX9 in NIH3T3 cells. A, the various COL9A1 promoterdeletion constructs (Fig. 3A) were co-transfected into NIH/3T3 cells
with 2 g of pBluescript vector or with a SOX9 expression vector and 2
g of the pCMV␤ plasmid. B, transactivation of the 846Luc construct in
NIH/3T3 cells by L-SOX5 and SOX6. NIH/3T3 cells were co-transfected
with 7 g of the 846Luc construct and either 2 g of pBluescript or
expression vectors for L-SOX5, SOX6, or SOX9 and 2 g of the pCMV␤
plasmid. Transfected cells were incubated for 48 h, and luciferase and
␤-galactosidase activities were determined as described under “Materials and Methods.” Data are presented as average -fold difference of
luciferase activity versus control (846Luc alone) vector ⫾ S.D.

co-transfected into NIH/3T3 cells along with a SOX9 expression
vector. Fig. 4A shows the results of this experiment. All of the
deletion constructs except for the 107Luc construct, which does
not contain any SOX/Sry-binding sites, were transactivated by
SOX9 overexpression. The full-length 846Luc construct displayed the strongest response to SOX9 co-transfection, exhibiting a ⬃30-fold increase in activity, whereas the deletion constructs that contained at least one putative SOX/Sry-binding
site (588Luc, 560Luc, 357Luc, and 167Luc) displayed a 15- to
20-fold increase in activity over control.
Two other SOX proteins, L-SOX5 and SOX6 have been shown
to cooperate with SOX9 in the transcriptional activation of the
COL2A1 gene through the intronic enhancer region (6). To
determine whether L-SOX5 and SOX6 play a role in the activation of the COL9A1 proximal promoter region, the 846Luc
construct was co-transfected into NIH/3T3 cells with L-SOX5,
SOX6, and SOX9 expression constructs. Fig. 4B demonstrates
that neither L-SOX5 or SOX6 alone or in combination activate
the COL9A1 proximal promoter. Interestingly, when L-SOX5,
SOX6, and SOX9 were co-transfected together with the 846Luc
construct, transactivation of the promoter was attenuated as
compared with co-transfection with SOX9 alone (Fig. 4B).
Mutations in the SOX/Sry-binding Sites Suppress Transcriptional Activation—To define more precisely the role of the
putative SOX/Sry-binding sites within the COL9A1 proximal
promoter region, point mutations were introduced into sites C,
D, and E (Fig. 5A). In each case, a 4-bp change was introduced
into the core SOX/Sry-binding sites employing PCR-based mutagenesis. The intact (wild-type) promoter construct (846Luc)
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FIG. 3. Deletion analysis of the human COL9A1 proximal promoter region in RCS cells. A, schematic illustration of the various
5⬘-deletion constructs employed in the analyses. The deletion constructs
were generated as described under “Materials and Methods.” B, relative
luciferase activity of the COL9A1 promoter-deletion constructs in RCS
cells. RCS cells were transfected with 10 g of each deletion construct
and 2 g of the pCMV␤ plasmid. Transfected cells were incubated for
48 h, and luciferase and ␤-galactosidase activities were determined as
described under “Materials and Methods.” Data are presented as average percent of control (846Luc) ⫾ S.D. Data represent 3– 4 experiments
performed in triplicate.
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and each of the mutant constructs (CmutLuc, DmutLuc, and
EmutLuc) were transfected separately into RCS cells to assess
the effect of the mutations on promoter activity. Fig. 5B demonstrates that mutations in site C had no effect on COL9A1
promoter activity. In contrast, mutations in sites D and E
reduced the promoter activity to 17 and 36% of control, respectively. Similarly, in co-transfection experiments with a SOX9
expression vector, the wild-type 846Luc and CmutLuc constructs were transactivated ⬃30- to 35-fold over control (Fig.
5C), whereas the DmutLuc and EmutLuc constructs were activated to only 1/3 of those levels (10- to 12-fold, Fig. 5C) by
SOX9 co-transfection. These results demonstrate that the SOX/
Sry-binding sites D and E are necessary for full promoter
activity in RCS cells and for full transactivation by SOX9 in
NIH/3T3 cells.
Although the results from the deletion analysis indicated
that the region encompassing site C was important for full
activity (construct 357Luc, Fig. 3B), the mutational studies
were contradictory because they showed that site C itself was
dispensable for promoter activity (CmutLuc construct, Fig. 5, B
and C). To clarify these results, either an 85-bp fragment
encompassing site C or a 96-bp fragment encompassing site D
(see brackets in Fig. 2A) were inserted into the pGL3promoter
vector, which contains the SV40 promoter (pGL3proC and
pGL3proD, Fig. 6A). When these constructs were transfected into
RCS cells, the pGL3proC construct displayed essentially the
same activity as the pGL3promoter vector alone, whereas the
pGL3proD construct was ⬃16-fold more active (Fig. 6B). We
conclude that along with SOX/Sry binding sites D and E, there
must be another positive-acting element within the promoter
region from ⫺560 to ⫺357 relative to the transcriptional start
site that is necessary for full promoter activity in RCS cells.
SOX9 Specifically Binds to SOX/Sry-binding Site D—To
determine whether SOX9 interacts with the putative SOX/Sry-
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FIG. 5. Mutations in the SOX/Srybinding sites D and E reduce transcriptional activity and transactivation of the COL9A1 promoter by
SOX9 in RCS and NIH/3T3 cells. A,
schematic illustration of the point mutations introduced into the SOX/Sry binding
sites C, D, and E, to generate constructs
CmutLuc, DmutLuc, and EmutLuc. B,
mutations in sites D and E reduce transcriptional activity of the COL9A1 promoter in RCS cells. The wild-type 846Luc
construct or the CmutLuc, DmutLuc, and
EmutLuc constructs (10 g) were transfected into RCS cells along with 2 g of
the pCMV␤ plasmid. C, mutations in sites
D and E reduce the transactivation by
SOX9 in NIH/3T3 cells. The wild-type
846Luc construct or the CmutLuc, DmutLuc, and EmutLuc constructs (10 g)
were co-transfected into NIH/3T3 cells
along with 2 g of pBluescript or a SOX9
expression vector and 2 g of the pCMV␤
plasmid. Transfected cells were incubated
for 48 h, and luciferase and ␤-galactosidase activities were determined as described under “Materials and Methods.”
Data are presented as average percent
luciferase activity of control (846Luc) ⫾
S.D. or as average -fold difference of luciferase activity versus control (846Luc, no
SOX9) ⫾ S.D.

FIG. 6. SOX/Sry-binding site-D can activate a heterologous
promoter in RCS cells. A, schematic illustration of the
pGL3promoter constructs in which fragments encompassing sites C
or D were placed in front of the SV40 promoter (see bracketed regions
in Fig. 2A). B, transfection of RCS cells with the pGL3promoter,
pGL3proC, or the pGL3proD constructs. Ten micrograms of either the
pGL3promoter, pGL3proC, or the pGL3proD construct along with 2
g of the pCMV␤ plasmid were transfected into RCS cells. Transfected cells were incubated for 48 h, and luciferase and ␤-galactosidase activities were determined as described under “Materials and
Methods.” Data are presented as average -fold difference of luciferase
activity versus control (pGL3promoter) ⫾ S.D.
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binding site-D, nuclear extracts were prepared from NIH/3T3
cells that had been transfected with SOX9 expression constructs, and electrophoretic mobility shift assays were performed. Fig. 7A shows the sequence of the SOX/Sry-binding site
D probe used in these experiments. Fig. 7B shows that specific
binding to probes containing SOX/Sry-binding site D or to a
probe containing the SOX binding sites from the COL2A1 gene
enhancer region were detected only in NIH/3T3 cells that had
been transfected with a SOX9 expression construct and not in
control cells. Competition analysis revealed that a specific
DNA-protein complex forms with SOX/Sry-binding site-D in
nuclear extracts from RCS cells, and this complex can be competed for with excess wild-type SOX/Sry-binding site-D probe
and excess probe containing the SOX-binding sites from the
human COL2A1 gene but not with a mutant SOX/Sry-binding
site-D probe (Fig. 7C). Finally, the DNA-protein complex that
forms with the wild-type SOX/Sry-binding site-D probe and
nuclear extract from NIH/3T3 cells transfected with a SOX9
expression construct can be supershifted with anti-SOX9 antibodies (Fig. 7D).
DISCUSSION

We demonstrate here that the proximal-promoter region of
the human COL9A1 gene can drive expression of a reporter
gene in chondrocytic RCS cells but not in the nonchondrocytic
HTB and NIH/3T3 cell lines. We also showed that the COL9A1
proximal-promoter region can be transactivated by SOX9 and
that the transactivation depends, in part, on two SOX/Srybinding sites (sites D and E). Also, full promoter activity depends on a region located between ⫺560 to ⫺357 relative to the
transcriptional start site. Further work revealed that SOX9
can specifically bind to at least one of the two sites (SOX/Sry-

binding site-D) as demonstrated by EMSA competition and
supershift analyses. Our results strengthen the notion that
SOX9 is a master regulatory factor for chondrocyte-specific
gene expression.
An interesting difference between the regulation of the
COL9A1 versus the COL2A1 promoter was observed when the
L-SOX5 and SOX6 expression constructs were included in
the co-transfection experiments. L-SOX5 and SOX6 did not
stimulate the transcriptional activity of our COL9A1 promoter
construct either alone or in combination. Even more intriguing
was the finding that when the L-SOX5 and SOX6 vectors were
co-transfected along with the SOX9 expression vector, the activity of the COL9A1 promoter was attenuated. In contrast to
this, L-SOX5 and SOX6 have been shown to stimulate the
transcriptional activity of the COL2A1 enhancer either alone or
in combination (6). Furthermore, when L-SOX5 and SOX6 are
expressed along with SOX9 in co-transfection assays, the activity of the COL2A1 gene was stimulated in an enhancer-dependent fashion to higher levels than that observed with the
individual SOX factors (6). It is interesting to speculate that
this might be a mechanism by which the chondrocyte could
achieve different levels of COL9A1 and COL2A1 gene expression utilizing the same transcription factors. Indeed, a similar
type of regulation has been observed with respect to the
COL2A1 gene. The transcription factor cKrox was shown to
interact with multiple sites within the enhancer region, resulting in up-regulation of the gene in differentiated chondrocytes,
whereas cKrox-binding sites located in the promoter were responsible for down-regulation of the gene in de-differentiated
chondrocytes (2). However, the COL2A1 gene is also regulated
by other negatively acting transcription factors. The transcrip-
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FIG. 7. SOX9 specifically interacts with the SOX/Sry-binding site-D in the human COL9A1 promoter. A, sequence of the wild-type and
mutated SOX/Sry-binding site-D probes employed in the EMSA experiments. Nucleotides in bold indicate the SOX/Sry-binding site. B, a specific
DNA-protein complex forms with a probe encompassing the SOX/Sry-binding site D in NIH/3T3 cells transfected with a SOX9 expression construct.
Nuclear extracts were prepared from NIH/3T3 cells that had either been mock-transfected or transfected with a SOX9 expression vector. The
nuclear extracts were subjected to EMSA with either a labeled SOX/Sry-binding site-D probe (D) or a probe containing the SOX/Sry-binding sites
from the human COL2A1 gene enhancer (IIE). C, DNA-binding competition analysis of the SOX/Sry-binding site-D. EMSA was performed with
RCS nuclear extract and the addition of 50-fold excess unlabeled human COL2A1 enhancer probe (IIE), wild-type SOX/Sry-binding site-D probe
(WT), or mutated SOX/Sry-binding site-D probe (M). Arrow indicates specific DNA-protein complex that is competed with excess IIE and WT probes
but not with excess M probe. D, antibody supershift analysis of the SOX-Sry-binding site-D. Nuclear extracts from NIH/3T3 cells transfected with
a SOX9 expression construct were subjected to a antibody supershift assay with anti-SOX9 antibodies. Arrow indicates super-shifted SOX9-D-site
complex. Nuclear extracts were prepared and EMSAs were performed as described under “Materials and Methods.”
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ment of the SOX/Sry-binding sites within the proximal-promoter region versus an enhancer region or both.
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tion factor ␦EF1 has been shown to repress COL2A1 gene
expression through sites in the promoter region in limb-bud
mesenchymal cells before differentiation occurs (3). The zincfinger transcription factor ␣A-crystallin binding protein-1 is
also a negative regulator of the COL2A1 gene, acting through
sites located in the enhancer region (4). Certainly, more work is
needed to elucidate the complex network of control mechanisms involved in chondrocyte-specific gene expression.
The structure of the promoter for COL9A1 is reminiscent of
that of the COL11A2 gene. A cluster of five SOX/Sry-binding
sites were also characterized in the proximal promoter region
of the COL11A2 gene, located between ⫺742 bp and the transcriptional start site (27). These sites were found to bind a
specific protein complex in RCS nuclear extracts that contained
SOX9 and also were able to direct reporter gene expression to
cartilaginous tissues in transgenic mice (27). Other work has
implicated a 60-bp segment within the first intron that is
important for COL11A2 gene expression. This segment was
also shown to interact with SOX9 and promote cartilage-specific expression of reporter genes in transgenic mice (28). Interestingly, the SOX/Sry sites located in the COL11A2 proximal promoter region differ from the sites studied in the present
work in that they are much closer to one another. Furthermore,
we found that the first intron of the COL9A1 gene did not
augment the activity of the promoter region. However, our
experiments do not rule out a role for the first intron in regulating COL9A1 gene expression in vivo because we have not
investigated the activity of the COL9A1-reporter constructs in
the context of transgenic mice.
As mentioned above, the arrangement of the SOX/Sry-binding sites within the COL9A1 proximal-promoter region differ
from those found in the COL11A2 promoter and also from the
SOX/Sry-binding sites located in the COL2A1 intronic enhancer (5– 8, 27–30). In the case of the COL11A2 gene, the five
SOX/Sry-binding sites are found within a region of ⬃130 bp
(27). However, the distal three sites are within 45 bp, and the
proximal two sites are separated by only 3 bp. Similarly, the
four SOX/Sry-binding sites within the COL2A1 intronic enhancer are spaced over a 48-bp region (5– 8). In contrast to this,
the five SOX/Sry-binding sites within the COL9A1 promoter
span a region of 565 bp. The transient-transfection studies
presented here rule out sites A and B as being important for
full promoter activity; however, the remaining three SOX/Srybinding sites are scattered over a 415-bp stretch, still substantially less compact than the COL11A2 and COL2A1 genes.
Whether this arrangement has any bearing on the relative
levels of expression of these genes or the developmental timing
of their expression remains to be determined, as does the place-
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